Jennison Associates
EW icon

Jennison Associates’s Edwards Lifesciences EW Stock Holding History

Jennison Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,800,000
Closed -$20.2M – 698
2013
Q2 		$20.2M Buy
+1,800,000
New +$21.3M 0.02% 430

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Jennison Associates's EW Position: Q2 2026 in Review

Jennison Associates reduced its Edwards Lifesciences (EW) stake by 98% in Q2 2026, selling an estimated $1.07B and leaving 238,403 shares worth $21.6M. The position accounts for 0.01% of the portfolio, ranked #328.

Jennison Associates first reported a position in EW in Q2 2015 and has held it in 27 quarters since. The position peaked at $1.34B in Q3 2019. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Jennison Associates held 238,403 shares of Edwards Lifesciences worth $21.6M as of Q2 2026.
  • Jennison Associates sold 12,827,871 Edwards Lifesciences shares in Q2 2026, an estimated $1.07B.
  • Edwards Lifesciences made up 0.01% of Jennison Associates's portfolio in Q2 2026, its #328 holding.
  • Jennison Associates first reported a position in Edwards Lifesciences in Q2 2015 and has held it in 27 quarters since.
  • Jennison Associates's Edwards Lifesciences position peaked at $1.34B in Q3 2019.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.